Asociación Madrileña de Hematología y Hemoterapia

Ensayos Clínicos Activos
de Hematología y Hemoterapia en la Comunidad de Madrid

Borrar filtro

Listado de Ensayos Clínicos ordenados por  
Recientes

Se han encontrado 813 ensayos

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1) Reclutando

Fase
Fase III
Patología
Leucemia mieloide aguda
Centros investigadores
H. Fundación Jiménez Díaz
H.G.U. Gregorio Marañón
MD Anderson Cancer Center Madrid
H.U. Ramón y Cajal
H.U. La Paz
Descripción
- To evaluate if revumenib + IC (intensive chemotherapy) improves EFS (event-free survival) compared to placebo + IC. - To evaluate if revumenib + IC improves MRDBM (-) (Measurable Residual Disease i...

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Reclutando

Fase
Fase III
Patología
Leucemia mieloide aguda, Trasplante de progenitores hematopoyéticos, Trombosis y Anticoagulantes, Linfoma, Leucemia
Centros investigadores
H. Fundación Jiménez Díaz
H.U. Infanta Leonor
H.U. 12 de Octubre
MD Anderson Cancer Center Madrid
Descripción
Nonintensive Therapy Study - To evaluate the effect of ziftomenib combined with SOC ven+aza on patient survival in untreated NPM1 m AML Intensive Therapy Study (7+3) - To evaluate the effect of zifto...

A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction (SEVENAZA) Reclutando

Fase
Fase III
Patología
Leucemia linfática crónica y otros SLPC, Leucemia mieloide aguda, Linfoma, Leucemia
Centros investigadores
H. Fundación Jiménez Díaz
H.U. 12 de Octubre
Descripción
To demonstrate the non-inferiority of a reduced VEN exposure to 7 days of AZA every 28 days cycle from the first cycle in terms of composite complete remission rate (complete remission + complete remi...

A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel Reclutando

Fase
Fase II
Patología
Leucemia mieloide aguda, Mieloma Múltiple y otras gammapatías, --> Otros, Terapia celular y T-CARs, Trasplante de progenitores hematopoyéticos, Trombosis y Anticoagulantes, Linfoma Folicular, Enfermedad de células falciformes, Linfoma
Centro investigador
H.U. 12 de Octubre
Descripción
To characterize the efficacy of cilta-cel infusion following a fludarabine free LD regimen (Cohort A) or a low-dose cilta-cel infusion following a standard cyclophosphamide and fludarabine LD regimen...

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody Reclutando

Fase
Fase III
Patología
Leucemia mieloide aguda, Linfoma no Hodgkin, Mieloma Múltiple y otras gammapatías, --> Otros, Terapia celular y T-CARs, Trasplante de progenitores hematopoyéticos, Micosis Fungoide, Linfoma Folicular, Enfermedad de células falciformes, Linfoma
Centros investigadores
H.U. Quirónsalud Madrid
H.U. 12 de Octubre
Descripción
To compare the efficacy of JNJ-79635322 with a BCMAxCD3 bispecific antibody.

Phase III, randomized, open-label, single-site clinical trial to evaluate the efficacy and safety of enoxaparin as a prophylactic treatment for localized intravascular coagulopathy and the impact of endothelial damage markers in patients aged 0 to 18 years with slow-flow vascular malformations undergoing percutaneous interventional procedures (PEaRL-X) Reclutando

Fase
Fase III
Patología
Coagulopatías hemorrágicas, Leucemia linfática crónica y otros SLPC, Leucemia linfoblástica aguda, Leucemia mieloide aguda, Linfoma
Descripción
To evaluate the efficacy and safety of enoxaparin in the prevention of localized intravascular coagulopathy and its complications during percutaneous interventional procedures in pediatric patients wi...

The SOUND-MCL study: A single-arm, open-label, multicenter, phase II study of acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain Reclutando

Fase
Fase II
Patología
Linfoma Folicular, Linfoma
Centros investigadores
H.G.U. Gregorio Marañón
H.U. de La Princesa
H.U.F. de Alcorcón
H.U. La Paz
Hospital Ruber Juan Bravo
Descripción
To assess the efficacy in terms of treatment response to acalabrutinib, in combination with the R-CHOP standard of care, in subjects with previously untreated MCL.

A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Reclutando

Fase
Fase II-III
Patología
Mieloma Múltiple y otras gammapatías
Centros investigadores
H.G.U. Gregorio Marañón
H.U. 12 de Octubre
H.U. Ramón y Cajal
Descripción
Phase 2: To determine the RP3D of etentamig in combination with daratumumab in partcipants with Newly Diagnosed Multiple Myeloma (NDMM) that are not eligible for transplant Phase 3: To evaluate the ef...

A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety. Un ensayo aleatorizado multicéntrico de fosfomicina frente a ciprofloxacino para la neutropenia febril en pacientes hematológicos: eficacia y seguridad microbiológica. En marcha

Fase
Fase III
Patología
Leucemia mieloide aguda, Terapia celular y T-CARs, Trasplante de progenitores hematopoyéticos, Linfoma, Leucemia
Centros investigadores
H. Fundación Jiménez Díaz
H.U. Clínico San Carlos
H.U. La Paz
Descripción
Treatment will be discontinued upon the occurrence of any of the following events: 1) febrile neutropenia requiring antibacterial treatment (study endpoint).2) Absolute Neutrophil Count (ANR) >0.5x109...

Esta web utiliza 'cookies' propias y de terceros para ofrecerte una mejor experiencia y servicio. Al navegar o utilizar esta plataforma, aceptas el uso que hacemos de ellas. Puedes cambiar tu propia configuración de 'cookies' en cualquier momento. Si continúas navegando, consideramos que aceptas el uso de cookies.

Aceptar